Approval · Notice of Compliance 465 · 2003
FRAGMIN: Notice of Compliance 465
Issued September 15, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 465
- Date
- September 15, 2003
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Anticoagulant / antithrombotic agent
Products in this notice
Medicinal ingredients
- DALTEPARIN SODIUM 10,000 UNIT per ML
- DALTEPARIN SODIUM 25,000 UNIT per ML
- DALTEPARIN SODIUM 2,500 UNIT per 0.2ML
- DALTEPARIN SODIUM 5,000 UNIT per 0.2ML